These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 21436679

  • 1. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
    Vranic S, Gurjeva O, Frkovic-Grazio S, Palazzo J, Tawfik O, Gatalica Z.
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.
    Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A.
    Hum Pathol; 2009 Nov; 40(11):1528-33. PubMed ID: 19695680
    [Abstract] [Full Text] [Related]

  • 5. Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.
    Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LM, Gatalica Z.
    Hum Pathol; 2010 Nov; 41(11):1617-23. PubMed ID: 20688355
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
    Gatalica Z.
    Pathol Res Pract; 1997 Nov; 193(11-12):753-8. PubMed ID: 9521507
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
    Honma N, Takubo K, Akiyama F, Sawabe M, Arai T, Younes M, Kasumi F, Sakamoto G.
    Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast.
    Honma N, Takubo K, Arai T, Younes M, Kasumi F, Akiyama F, Sakamoto G.
    APMIS; 2006 Oct; 114(10):712-9. PubMed ID: 17004974
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The expression of GHRH and its receptors in breast carcinomas with apocrine differentiation-further evidence of the presence of a GHRH pathway in these tumors.
    Kővári B, Vranic S, Marchio C, Sapino A, Cserni G.
    Hum Pathol; 2017 Jun; 64():164-170. PubMed ID: 28438614
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
    Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z.
    Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
    [Abstract] [Full Text] [Related]

  • 20. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
    Bhargava R, Beriwal S, Striebel JM, Dabbs DJ.
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.